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Abstract
Background: The steroid and xenobiotic receptor, SXR, is an orphan nuclear receptor that
regulates metabolism of diverse dietary, endobiotic, and xenobiotic compounds. SXR is expressed
at high levels in the liver and intestine, and at lower levels in breast and other tissues where its
function was unknown. Since many breast cancer preventive and therapeutic compounds are SXR
activators, we hypothesized that some beneficial effects of these compounds are mediated through
SXR.
Methods: To test this hypothesis, we measured proliferation of breast cancer cells in response to
SXR activators and evaluated consequent changes in the expression of genes critical for
proliferation and cell-cycle control using quantitative RT-PCR and western blotting. Results were
confirmed using siRNA-mediated gene knockdown. Statistical analysis was by t-test or ANOVA and
a P value ≤ 0.05 was considered to be significant.
Results: Many structurally and functionally distinct SXR activators inhibited the proliferation of
MCF-7 and ZR-75-1 breast cancer cells by inducing cell cycle arrest at the G1/S phase followed by
apoptosis. Decreased growth in response to SXR activation was associated with stabilization of p53
and up-regulation of cell cycle regulatory and pro-apoptotic genes such as p21, PUMA and BAX.
These gene expression changes were preceded by an increase in inducible nitric oxide synthase and
nitric oxide in these cells. Inhibition of iNOS blocked the induction of p53. p53 knockdown
inhibited up-regulation of p21 and BAX. We infer that NO is required for p53 induction and that
p53 is required for up-regulation of cell cycle regulatory and apoptotic genes in this system. SXR
activator-induced increases in iNOS levels were inhibited by siRNA-mediated knockdown of SXR,
indicating that SXR activation is necessary for subsequent regulation of iNOS expression.
Conclusion: We conclude that activation of SXR is anti-proliferative in p53 wild type breast
cancer cells and that this effect is mechanistically dependent upon the local production of NO and
NO-dependent up-regulation of p53. These findings reveal a novel biological function for SXR and
suggest that a subset of SXR activators may function as effective therapeutic and chemo-
preventative agents for certain types of breast cancers.
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Background
Anti-estrogens such as tamoxifen are important therapeu-
tic agents in the treatment and chemoprevention of breast
cancer [1]. Other compounds such as fatty acid amides
and retinoid × receptor (RXR) agonists are also effective
against breast cancer in cell lines and in animal models
[2,3]. Interestingly, a macrolide antibiotic-rifampicin, the
antimycotic drug clotrimazole, endogenous cannabinoids
such as anandamide, RXR agonists (rexinoids) such as tar-
gretin, and tocotrienol forms of Vitamin E share the abil-
ity to inhibit the growth of various types of cancer [2-8].
Some of these compounds such as rifampicin, targretin,
and tocotrienols have also been shown to have synergistic
or additive effects against cancer when used together with
tamoxifen [4,7,9]. Although it is certainly possible that
they act through separate and distinct pathways, the abil-
ity of these structurally and functionally distinct com-
pounds to inhibit the growth of cancer cells and their
additive effects with tamoxifen raise the possibility that
they might also act through a common molecular target.
Notably, these compounds (including tamoxifen) share
the ability to activate a heterodimer of the steroid and
xenobiotic receptor (SXR [10], also known as PXR [11],
PAR [12], and NR1I2 [13]) and retinoid × receptor (RXR)
[14].
SXR is an orphan nuclear receptor activated by a large
number of endogenous steroids and bile acids, prescrip-
tion drugs, dietary compounds and xenobiotic com-
pounds [15-18]. SXR is highly expressed in the liver and
intestine where it acts as a broad-specificity chemical sen-
sor. SXR activation induces expression of genes involved
in all three phases of drug and xenobiotic metabolism:
hydroxylation by cytochrome P450 enzymes, conjugation
to glutathione, sulfates and sugars, and transport by ABC
family transporters (reviewed in [19-21]). We and others
have shown that SXR is also expressed in tissues such as
bone, kidney, lung, endometrium, and breast [22-26],
where it may play roles other than its conventional role in
metabolism. For example, activation of SXR in bone is
associated with increased expression of bone biomarkers
involved in maintaining bone homeostasis [27,28]. SXR
activation in liver is associated with decreased fibrogene-
sis and increased expression of anti-apoptotic genes such
as BCL2 and BCL-XL [29-31]. Expression of SXR in
endometrial cancer tissues is associated with decreased
sensitivity to anti-cancer agents [22,32]. Recently, one
report has shown that activation of SXR leads to height-
ened sensitivity to oxidative cellular damage and apopto-
sis in transgenic mice and in cancer cells [33]. Another
suggested an anti-apoptotic role for SXR in colon cancer
cells and in normal mouse colon epithelium [34]
SXR is expressed in breast cancer cells and tissues [23,25].
The expression of SXR in breast cancer cells and tissues
and the ability of numerous compounds active against
breast cancer to activate SXR led us to hypothesize that
SXR might serve as a common molecular target for their
action. Here we show that SXR activation can inhibit
breast cancer cell growth by inducing cell cycle arrest and
apoptosis. We define a molecular pathway wherein activa-
tion of SXR inhibits proliferation of estrogen receptor pos-
itive (ER+) and p53 wild type (p53wt) breast cancer cell
lines (MCF-7 and ZR-75-1) via induction of inducible
nitric oxide synthase (iNOS), increased expression of
nitric oxide (NO), and NO-dependent stabilization and
accumulation of p53. SXR-mediated stabilization of p53
protein and up-regulation of p53 mRNA leads to
increased expression of p53-dependent cell cycle regula-
tors and pro-apoptotic genes such as p21, BAX and PUMA.
Gain- and loss-of-function studies confirm that SXR is the
mediator of this pathway. We conclude that activation of
SXR is anti-proliferative in MCF-7 and ZR-75-1 breast can-
cer cells and that these effects are mediated through a NO
and p53-dependent pathway. Our results identify a novel
molecular pathway for SXR action in breast cancer and
widen the biological relevance of SXR beyond xenobiotic
metabolism.
Methods
Cell culture
Rifampicin, anandamide and camptothecin were from
BioMol (Plymouth Meeting, PA) and all other com-
pounds were from Sigma. Compounds were freshly
diluted in DMSO prior to addition to cell culture media.
The final DMSO concentration was < 0.05%. Breast cancer
cell lines were maintained in phenol red free Improved
Minimum Essential Media (IMEM; Mediatech, Kansas
City, MO) supplemented with 10% fetal bovine serum
(FBS; Invitrogen Corporation) (IMEM/FBS). LS180 cells
were maintained in Dulbecco Modified Eagle Medium
(DMEM; Cellgro) supplemented with 10% FBS.
Quantitative real-time RT-PCR
Cell lines were treated with SXR ligands for the indicated
times followed by isolation of total cellular RNA using Tri-
zol reagent (Invitrogen). After removal of potentially con-
taminating genomic DNA by DNAse digestion and LiCl
precipitation, 1 μg total RNA was reverse transcribed using
Superscript III (Invitrogen) following the manufacturer's
recommended protocol. Quantitative real time RT-PCR
(QRT-PCR) was performed using primer sets as shown in
Table 1 using SYBR Green PCR Master Mix (Applied Bio-
systems, Foster City, CA) or FastStart SYBR Green Master
Mix (Roche Applied Science, Indianapolis, USA) in a DNA
Engine Opticon-Continuous Fluorescence Detection Sys-
tem (MJ Research, Reno, NV). All samples were quanti-
tated by the comparative cycle threshold C(t) method for
relative quantitation of gene expression, normalized to
either GAPDH or β-actin [35].BMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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Western blotting
Cells growing in culture were washed three times with ice-
cold PBS and then lysed in RIPA buffer (137 mM NaCl, 20
mM Tris-HCl, pH 7.5, 1% Triton X-100, 0.5% NP-40, 10%
glycerol, 2 mM EDTA, pH 8.0) plus protease inhibitors
(Roche). Lysate protein concentrations were determined
using the Bradford method and equal amounts of protein
were separated on 8–10% SDS-polyacrylamide gels. For
CaM protein, the proteins were separated on 4–20% gra-
dient Tris-HCl gels. Proteins were transferred to Immo-
bilon membrane (Millipore) using the semi-dry method
(BioRad, Hercules, CA). Membranes were blocked for 1 hr
with 5% non-fat dried milk in TBST (25 mM Tris-HCl pH
7.4, 135 mM NaCl, 2.5 mM KCl, 0.1% Tween-20) and
then incubated overnight at 4°C with SXR (Anti-412, or
PP-H4417, Perseus Proteomics inc., Japan) or p53 (FL-
393 HRP, Santa Cruz Biotechnology Inc., USA) antibod-
ies. The membranes were fixed in 0.2% glutaraldehyde in
TBS for CaM protein before blocking in 3% BSA overnight
followed by 1 hr incubation in mouse monoclonal CaM
antibody (C-7055, Sigma-Aldrich, USA) at RT. The anti-
412 SXR antibody was raised against a synthetic peptide
sequence starting at amino acid 412 (CLRIQDIHPFAT-
PLMQE), by Bethyl Laboratories, Inc., Montgomery, TX.
Isolated IgG was affinity purified against this peptide prior
to use. The primary antibody incubation was followed by
1 hr incubation at room temperature with HRP-conju-
gated secondary antibody (1:10,000; Santa Cruz Biotech-
nology Inc., USA). The bands were detected using the ECL
Plus Western Blotting Detection System (Amersham Bio-
science, USA). Chemiluminescence was assayed using an
Alpha Innotech Fluorchem SP imager (Alpha Innotech
Inc., CA, USA) and analyzed by densitometry using
FluorChem AlphaEase FC software (Alpha Innotech).
Proliferation assays
MCF-7 cells were seeded at 500 cells/well and ZR-75-1
cells were seeded at 2500 cells/well in 96-well plates in
IMEM supplemented with 10% FBS. Cells were treated
with ligands at the indicated concentrations every other
day for seven days. Cell proliferation was measured using
a fluorescence assay (CyQuant, Molecular Probes) and a
Cytofluor 4000 Fluorescence Multi-Well Plate Reader
(PerSeptive Biosystems).
Flow Cytometry
MCF-7 cells were incubated with 10 μM of SXR agonists
(rifampicin, tamoxifen, anandamide, clotrimazole,
RU486) or DMSO solvent control for 24 h. Cells were sub-
sequently harvested using trypsin (0.5% w/v), centrifuged
(140 g for 12 min), washed with PBS, and fixed with 2 ml
ice-cold 70% ethanol overnight. Cells were centrifuged
and resuspended with 10 μg/ml Propidium Iodide and
100 μg/ml RNase A at 37°C for 30 min. Samples were
acquired on a FACSCalibur (BD Biosciences), and data
were analyzed by CellQuest (BD Biosciences) and FlowJo
(Tree Star, San Carlos, CA) software. Modfit (Verity Soft-
ware, Topsham, ME) software was used to quantitate cell
cycle using the fluorescence values of the FL2-area chan-
nel.
Detection of apoptosis
MCF-7 cells growing in culture were treated with 10 μM
SXR ligands for 24, 48 and 72 hrs. Cells were also treated
with 10 μM camptothecin for 24 hrs as a positive control
for apoptosis. After the indicated period of treatment, cells
were trypsinized and counted. Apoptosis was measured in
the cytoplasmic fraction of equal numbers of cells using
the Cell Death Detection ELISA (Roche Applied Science,
Germany) using the manufacturer's recommended proto-
col.
NOS activity in cell lysates
MCF-7 cells were treated with 10 μM rifampicin or DMSO
for indicated time periods. The cells were also treated with
a cocktail of IL-1β (20 ng/ml), TNFα (15 ng/ml) and LPS
(1 mg/ml) as a positive control for iNOS induction. After
the indicated time periods, cell lysates were made in 1×
Table 1: Primer sequences used in Q-RTPCR analysis
Name Forward Reverse
SXR AGGATGGCAGTGTCTGGAAC AGGGAGATCTGGTCCTCGAT
iNOS CACCATCCTGGTGGAACTCT TCCAGGATACCTTGGACCAG
eNOS GTTACCAGCTAGCCAAAGTC GACAGGAAATAGTTGACCATCTC
nNOS GAAGAAAGCAACCAGAGTCAG GTCCAAATCTCTGTCCACCT
p53 CCGCAGTCAGATCCTAGC AATCATCCATTGCTTGGGACG
p21 GCGATGGAACTTCGACTTTG CAGGTCCACATGGTCTTCCT
BAX GGGGACGAACTGGACAGTAA CAGTTGAAGTTGCCGTCAGA
PUMA GACCTCAACGCACAGTACGA CTAATTGGGCTCCATCTCG
CYP3A4 GGCTTCATCCAATGGACTGCA TAAAT TCCCAAGTATAACACTCTACACAGACAA
Calmodulin TTGACTTCCCCGAATTTTTGACT CTGCACTGATATAACCATTGCCA
β-actin GGACTTCGAGCAAGAGATGG AGGAAGGAAGGCTGGAAGAG
GAPDH GGCCTCCAAGGAGTAA AGGGGAGATTCAGTGTGGTGBMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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homogenization buffer (25 mM Tris-Hcl pH7.4, 1 mM
EDTA, 1 mM EGTA) by sonicating cells twice for 10 s at 10
amp. NOS activity was detected by measuring the conver-
sion of 14C L-arginine (Amersham Bioscience, USA) into
14C L-citrulline by using nitric oxide synthase assay kit
(Calbiochem Inc., USA). Radioactivity was measured by
liquid scintillation counting and normalized to protein
content.
Nitrite concentration in culture medium
NO production was measured as nitrite concentration in
cell culture supernatants using the Griess method [36].
Briefly, aliquots of media were removed from cells grow-
ing in culture in the presence or absence of SXR activators,
followed by centrifugation to remove cells. In the cell-free
supernatants nitrate, a stable metabolite of NO, was
reduced to nitrite by incubating sample aliquots for 15
min at 37°C in the presence of 0.1 U/ml nitrate reductase
(from Aspergillus species, Roche), 50 μM NADPH (Sigma,
USA) and 5 μM FAD (Sigma, USA). When nitrate reduc-
tion was complete, NADPH was oxidized to avoid inter-
ference with subsequent nitrite determination. For this
purpose, the reduced samples were incubated with 10 U/
ml L-lactate dehydrogenase (from rabbit muscle) and 10
mM sodium pyruvate for 5 min at 37°C, followed by
addition of 50 μl of 1% sulfanilic acid in 5% phosphoric
acid and 50 μl of 0.1% N-(1-naphthyl) ethylenediamine
dihydrochloride to 100 μl of the reduced cell-free super-
natant [36]. After 10 minutes at 23°C, the absorbance at
546 nM was determined. Concentrations of nitrite in sam-
ples were calculated from standard curves using sodium
nitrite as the reference compound.
RNA Interference
Small interfering RNA (siRNA) duplexes targeting human
SXR and p53 were custom synthesized by Qiagen (Qiagen
Inc. USA). The most effective SXR siRNA target sequence
was 5'-GGCCACTGGCTATCACTTC-3' [27,37] and p53
siRNA sequence was 5'-AAACCACTGGATGGAGAATA
TTT-3'. Non-silencing control siRNA sequence 5'-AAT-
TCTCCGAACGTGTCACGT-3' (Qiagen Inc. USA) was
used as a negative control. The cells were transfected using
Lipofectamine™ RNAiMAX transfection reagent (Invitro-
gen Inc., USA). The knock down efficiency by mRNA and
protein were determined after 48 and 72 hrs of transfec-
tion, respectively. For gene expression assays, the cells
were transfected with siRNA two day prior to ligand treat-
ment, or the day of ligand treatment. After 48 hr of treat-
ment with SXR ligands, RNA was isolated, cDNA
synthesized and QRT-PCR analysis performed.
Statistical analyses
Data are shown as the mean values ± SEM. Results of two
groups were analyzed using "unpaired" Student's t tests.
Multiple comparisons were analyzed using one-way anal-
ysis of variance (ANOVAs). P ≤ 0.05 was taken to be sta-
tistically significant.
Results
SXR mRNA and protein are expressed in breast cancer cell 
lines
A variety of different classes of compounds that are able to
transcriptionally activate SXR (e.g., anandamide, rexi-
noids, tamoxifen) have been previously observed to slow
the proliferation of breast cancer cell lines and/or slow
tumor growth in rodent models of breast cancer
[3,4,7,38]. Previous work and our preliminary results
showed that SXR was expressed in human breast cancers
and in some breast cancer cell lines [23,25]. Therefore, we
hypothesized that SXR activation might mediate some of
the anti-proliferative effects of these compounds in breast
cancer. We first surveyed the expression of SXR in two
established breast cancer cell lines, MCF-7 and ZR-75-1.
SXR mRNA was present in both cell lines and the level of
SXR mRNA was lower in the breast cancer cells than in the
positive control colon carcinoma cell line LS180 (Figure
1A). However, SXR expression is known to be high in the
liver and gut where it regulates the xenobiotic response
[10,39].
Considering the relatively low levels of SXR mRNA found
in breast cancer cells, western blot analysis of cell lysates
was employed to confirm that SXR protein was, in fact,
expressed. In agreement with the QRT-PCR data, SXR pro-
tein was present in both breast cancer cell lines (for char-
acterization of the antibody, see Additional file 1:
supplementary Figure 1). Consistent with these findings,
MCF-7 and ZR-75-1 cells treated with 10 μM of the SXR
activators rifampicin, anandamide or clotrimazole for 48
hours showed induction of the well-characterized SXR tar-
get gene CYP3A4 by QRT-PCR, demonstrating the func-
tionality of endogenous SXR in these cells (data not
shown). The kinetics of CYP3A4 up-regulation (48 hour
post-treatment) by SXR activators matches with previ-
ously reported timing for its induction by SXR activators
in osteosarcoma cells [24], where its activation induces
genes involved in bone homeostasis.
SXR activation reduces the proliferation of breast cancer 
cell lines
Next, to test our hypothesis that SXR might play a role in
some of the anti-proliferative effects previously observed
by different classes of compounds (e.g., anandamide, rex-
inoids, tamoxifen); we did an initial screening experiment
in which we tested a large number of structurally and
functionally diverse compounds that all share the ability
to activate SXR. We hypothesized that similar effects elic-
ited by these distinct compounds could be through a com-
mon, SXR-mediated mechanism. For this purpose, the
breast cancer cell lines, MCF-7 and ZR-75-1 were treatedBMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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SXR mRNA and protein are expressed in breast cancer cell lines Figure 1
SXR mRNA and protein are expressed in breast cancer cell lines. A) Total RNAs from breast cancer cell lines, MCF-
7 and ZR-75-1 and colon carcinoma cell line LS180 were isolated, reverse transcribed and subjected to QRT-PCR analysis 
using primers for human SXR. Values represent the average of triplicates ± S.E.M. and were replicated in at least three inde-
pendent experiments. B) Equal amounts of total cell lysates (30 μg-in each lane) were separated by SDS-PAGE followed by 
Western blot analysis using the rabbit polyclonal anti-SXR (anti-412) antibody. The blot was stripped and re-probed with anti-
GAPDH antibody (mouse monoclonal 6C5, Ambion, Inc., Austin, TX) as a loading control. The results were replicated in at 
least three independent runs.
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with compounds such as macrolide antibiotic rifampicin;
which is a human selective SXR activator [10], the anti-
estrogen tamoxifen; which is also an SXR agonist [14,40],
the fatty acid ethanolamide anandamide, the anti-fungal
clotrimazole [41] or the calcium channel blocker nifed-
ipine [42]. Prior to treatment, the ability of these com-
pounds to activate SXR was confirmed in transient
transfection assays (see Additional file 1: supplementary
Figure 2A). The phtoestrogen-rutin did not activate SXR in
transfection assays so that was chosen as a negative con-
trol for the experiment.
To determine the dose dependent effect of SXR activators
on proliferation, breast cancer cells were cultured in the
presence of a concentration series (1, 10 and 100 μM) of
test compounds or controls (solvent, rutin). To measure
the integrated effect on cell cycle and/or cell survival in the
presence of SXR activators the proliferation assays were
continued until 7 days which was the time when the cells
in the solvent control wells just reached confluency. Inter-
estingly, SXR activators elicited a dose-dependent reduc-
tion in proliferation of both cell types (Figure 2A). The
rank order of potency in the proliferation assay agreed
well with the potency and efficacy of these compounds as
SXR activators. For example, rifampicin, which was the
best activator of SXR in transfection assays, also had the
highest ability to inhibit proliferation of breast cancer
cells in proliferation assay. Rutin, which did not activate
SXR in transfection assays, lacked any effect on prolifera-
tion of cancer cells (Figure 2A and Additional file 1: sup-
plementary Figure 2). The anti-proliferative effects of
tamoxifen were more pronounced than its ability to acti-
vate SXR, but, as both of the tested breast cancer cell lines
are estrogen receptor positive, it is likely that some of the
observed effects are mediated through an ER-dependent
mechanism.
SXR activation induces apoptosis and cell cycle arrest in 
breast cancer cells
The decreased proliferation observed in breast cancer cell
lines treated with SXR activators could be due to inhibi-
tion of proliferation, increased cell death or both. To
determine the earlier molecular events responsible for the
ultimate effect on cell number, we first examined the
effects of SXR activator treatment on the cell cycle using
flow cytometry. In proliferation assays, the growth inhib-
itory effects of SXR activators were obvious at doses as low
as 10 μM (Figure 2A). Therefore, we chose a 10 μM dose
of SXR activator compounds for all further experiments.
MCF-7 cells were treated with SXR activators rifampicin,
tamoxifen, anandamide, clotrimazole, RU486 [41] or sol-
vent control for a time course of 12, 24 and 48 hrs so that
the earlier molecular events can be detected within one or
two cell cycles. Cellular DNA content was measured by
propidium iodide staining followed by FACS analysis. All
SXR activator treated MCF-7 cells exhibited a consistent
increase in the fraction of cells in the G0/G1 phase of the
cell cycle compared with controls starting at 24 hours, sug-
gesting that they are arrested at G0/G1 (Figure 2B). The
cells treated with SXR activators accumulated more in G1/
S phase at 48 hr but the cells in solvent control also
increased in G1/S phase at 48 hr time point, suggesting
that the solvent control cells have started to get confluent
at that time. The SXR activators consistently had more
cells in G1/S phase than did solvent controls, suggesting
that SXR activators can specifically cause G1/S arrest in
breast cancer cells (data not shown).
This finding is consistent with published results showing
that tamoxifen (an anti-estrogen and SXR activator)
causes G0/G1 arrest in MCF-7 cells [43]. Although
tamoxifen, RU486 and nifedepine can activate SXR, they
can also affect ER and PR/GR and calcium homeostasis of
the cells respectively, which can have erroneous effects on
cell growth. To avoid unnecessarily confounding the
results, we decided to use only the antibiotic rifampicin,
the anti-fungal clotrimazole and the fatty acid amide
anandamide as SXR activators in subsequent experiments.
We next tested the effect of SXR activation on apoptosis
using a sandwich ELISA with anti-histone and anti-DNA
antibodies. Again MCF-7 cells were treated with 10 μM of
the SXR activators rifampicin, anandamide, clotrimazole
or solvent from 24–72 hours, or treated with 10 μM camp-
tothecin for 24 hours as a positive control for induction of
apoptosis. Each of the SXR activators increased the
amount of apoptosis observed in treated MCF-7 cells
beginning at 48 hours (Figure 2C). Therefore, we infer
that the decreased proliferation observed in MCF-7 cells is
caused by an increase in cell cycle arrest at G0/G1 phase
followed by apoptosis.
Treatment with SXR activators increases expression of p53 
and p53 target genes
SXR is a transcription factor; therefore, we next looked for
gene expression changes that resulted from the activation
of endogenous SXR that could ultimately result in either
apoptosis or cell cycle arrest. MCF-7 and ZR-75-1 cells
were treated with 10 μM rifampicin, anandamide, clot-
rimazole or solvent controls, and total RNA was prepared
after 24, 48 and 72 hours of incubation. The expression of
a panel of genes involved in apoptosis, control of cell pro-
liferation and cell cycle regulation were analyzed by QRT-
PCR. Interestingly, we found that expression of mRNAs
encoding p53 and three p53 target genes, p21, BAX and
PUMA [44], were increased by all three SXR activators in
both MCF-7 and ZR-75-1 cells. The changes in gene
expression were statistically significant by all three test
compounds by 72 hours in MCF-7 cells and by 24 hours
in ZR-75-1 cells (Figure 3A and Figure 3B). The p53BMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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SXR activation reduces proliferation of breast cancer cells Figure 2
SXR activation reduces proliferation of breast cancer cells. A) MCF-7 and ZR-75-1 cells were grown in the presence 
of 1, 10 or 100 μM concentrations of SXR activators. Rutin, an isoflavone that does not activate SXR, and DMSO solvent were 
used as negative controls. Cell proliferation was measured after seven days using a fluorescence assay wherein emission at 535 
nm is proportional to cell number. The values represent the average emission for triplicates ± S.E.M. These results were repli-
cated in independent experiments. ** represents P ≤ .01 and # represents P ≤ .001 in comparison to solvent control (by one way 
ANOVA analysis) B) SXR activators cause G0/G1 arrest as compared to DMSO solvent controls. MCF-7 cells treated with 10 
μM SXR activators for 24 hours were fixed, stained with propidium iodide and data acquired on FACSCalibur (BD Bio-
sciences). Data were analyzed by CellQuest (BD Biosciences) and FlowJo (Tree Star, San Carlos, CA) software. Modfit (Verity 
Software, Topsham, ME) software was used to quantitate cell cycle using the fluorescence values of the FL2-area channel. The 
experiment was repeated twice in duplicates and the numbers represent the average of four values. Note: to measure the cell 
cycle distribution the population was live gated. C) SXR activators cause apoptosis in MCF-7 cells starting at 48 hours post-
treatment. MCF-7 cells were grown in the presence of 10 μM SXR activators rifampicin, anandamide, or clotrimazole (RIF, 
ANA or CLO). Apoptosis was measured at 24, 48 and 72 h in the cytoplasmic fraction using the Cell Death Detection ELISA 
(Roche Applied Science, Germany). DMSO treatment was used as a negative control and 24 hour camptothecin (CAMP) treat-
ment was used as a positive control for apoptosis. The values represent average of triplicates ± S.E.M and the results were rep-
licated in two independent experiments. ** represents P ≤ .01 and # represents P ≤ .001 (by one way ANOVA analysis).

   
 	 	
 





	


















'()*+

 
+
,
*
 
!
-
"



	


-
(

*'.!(/'"'-
0!(,1'.-
!-!-#!('#
"2,0*'(!3,2
-'.#'/'-
*40'-
+,25-0





	

$ 


  
 







*'.!(/'"'-
0!(,1'.-
!-!-#!('#
"2,0*'(!3,2
-'.#'/'-
*40'-
+,25-0 




	

 






   

 




%
(
'
+
+
'
,
-





-

     






     




     

	




     




    
 






   



 

  

  
  



  	
     
  	
     


  
	
  
  

  
     
  

  
  	
  

  
    
  


 
 



2 2
+



2 2 +



2 2 +BMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
Page 8 of 19
(page number not for citation purposes)
Treatment with SXR activators increases expression of p53 and p53 target genes Figure 3
Treatment with SXR activators increases expression of p53 and p53 target genes. Total RNA was isolated from A) 
MCF-7 cells or B) ZR75-1 cells grown in the presence of 10 μM SXR activators rifampicin, anandamide, or clotrimazole (RIF, 
ANA or CLO) for 72 hours and 24 hours respectively. RNA was reverse transcribed and analyzed by QRT-PCR using primers 
for human p53, p21, BAX and PUMA. Data are depicted as average fold induction relative to solvent control in triplicates ± 
S.E.M. These results were replicated in at least three independent experiments. *represents P ≤ .05, **represents P ≤ .01 and # 
represents P ≤ .001 (by one-way ANOVA analysis). C) SXR activation causes p53 accumulation. Cell lysates made from C) 
MCF-7 and D) ZR-75-1 cells treated with SXR agonists (10 μM) or solvent controls for 72 and 24 hours respectively were sub-
jected to Western blot analysis using p53 antibody (FL-393 HRP, Santa Cruz Inc.). Equal loading was confirmed by stripping and 
re-probing the same blot with an anti-GAPDH antibody. Camptothecin (CAMP) 24 hour treatment was used as a positive con-
trol for p53 induction. The chemiluminescent bands were acquired by Alpha Innotech Fluorchem SP imager (Alpha Innotech 
Inc., CA, USA) and analyzed by spot densitometry analysis using FluorChem AlphaEase FC software (Alpha Innotech). The 
experiment was done in duplicates and the numbers represent the average from two independent runs. Note that the gap in 
ANA lane of ZR-75-1 is because of gel tearing at the time of transferring.
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expression went down by 72 hrs in response to all three
test compounds in ZR-75-1 cells (data not shown).
Increased expression of p21 induces cell cycle arrest or
apoptosis [45], whereas BAX and PUMA are promoters of
apoptosis [46-48]. Therefore, increased expression of BAX
and PUMA is consistent with the apoptosis observed.
Increased p21 is consistent with the G1 arrest observed in
MCF-7 cells. These molecular changes in both MCF-7 and
ZR-75-1 cells by all three test compounds led us to infer
that SXR can increase expression of p53 and several key
p53 target genes associated with apoptosis and inhibition
of cell proliferation in breast cancer cell lines.
We also tested the effects of SXR agonists on steady state
levels of p53 protein in MCF-7 and ZR-75-1 cells. Camp-
tothecin treatment for 24 hrs served as a positive control
for p53 induction. Treatment with each of the SXR activa-
tors resulted in increased p53 protein levels in both MCF-
7 (Figure 3C) and ZR-75-1 (Figure 3D) cells. Previous
reports showed that iNOS-mediated increases in nitric
oxide (NO) levels lead to p53 stabilization and activation
as a result of phosphorylation of p53 at ser-15 [49]. This
phospho-p53 is transcriptionally active and increases
expression of p21 and BAX [50,51]. Since iNOS is a
reported target gene of ligand-activated SXR [52], we fur-
ther investigated the idea that the mechanism linking SXR
activation with the observed effects on p53 and its target
genes involved iNOS expression and increased NO levels.
Inducible nitric oxide synthase expression and nitric oxide 
levels are increased by SXR activation
Although p53 mRNA expression is increased by treatment
with SXR activators, the time course of induction in
mRNAs encoding p53 and its target genes such as p21,
BAX and PUMA (72 hours post-treatment in MCF-7 cells,
and 24 hours post-treatment in ZR-75-1 cells) led us to
hypothesize that elevation of p53 mRNA levels and the
resulting changes in p53 target gene expression were a sec-
ondary response to an earlier primary effect of SXR activa-
tion. The p53 tumor suppressor can be activated or
stabilized in response to DNA damage or cellular stress
such as accumulation of reactive oxygen species (ROS) or
reactive nitrogen species (RNS) [53]. Moreover, RNS-sta-
bilized p53 has been shown to up-regulate both p21 and
BAX expression [50,51]. Nitric oxide itself increases
expression of p21 and causes late G1 arrest in cells
through p53-mediated and p53-independent pathways
[50,54]. Therefore, we considered the possibility that
treatment with the various SXR activators was increasing
the expression of a cellular stressor such as RNS. A previ-
ous report suggested that the promoter of inducible nitric
oxide synthase (iNOS/NOS2A) contained an SXR-respon-
sive element, and that increased expression of iNOS is a
primary and direct response to SXR activation [52]. Pro-
duction of iNOS increases the cellular levels of NO and
RNS and a significant association between iNOS and p53
expression has been demonstrated at the mRNA and pro-
tein levels [55]. Accordingly, we examined expression of
iNOS mRNA in MCF-7 and ZR-75-1 cells treated with SXR
activators. MCF-7 cells were treated with SXR activators for
24, 48, and 72 hours, whereas ZR-75-1 cells were treated
for 18 and 24 hours. These time points were selected
because they precede those at which we observed up-reg-
ulation of p53 and its target genes in these cells, thus
allowing the detection of prior events. We found that
three different SXR activators increased iNOS mRNA lev-
els in MCF-7 (Figure 4A) and ZR-75-1 cells (Figure 4B),
suggesting that SXR activation, per se, and not other prop-
erties of the compounds was increasing iNOS mRNA lev-
els. Increased iNOS expression was observed as early as 24
hours post-treatment in MCF-7 cells, whereas it could be
detected starting at 18 hrs in ZR-75-1 cells. iNOS expres-
sion subsequently decreased in clotrimazole treated MCF-
7 cells at 48 and 72 hours and in ZR-75-1 cells at 24 hrs.
This is likely due to the reported negative regulation of the
iNOS promoter by NO production and by activated p53
[56].
Under normal conditions, calmodulin (CaM) binding is
necessary for the stabilization and activation of iNOS.
When CaM levels are insufficient, newly synthesized
iNOS is rapidly degraded through the calpain and protea-
somal systems [57]. Therefore, we tested the expression of
CaM mRNA in MCF-7 cells treated with rifampicin or sol-
vent control for 3 hrs, 9 hrs, 12 hrs and 24 hrs and ZR75-
1 cells treated with rifampicin or solvent control for 3 hrs,
9 hrs, 12 hrs and 18 hrs using QRT-PCR. We observed a
transient up-regulation in steady state levels of CaM
mRNA at 9 hrs in MCF-7 cells and at 18 hours in ZR75-1
cells (see Additional file 1: supplementary Figure 3A and
3B). To further confirm that this transient increase in CaM
mRNA translated into sustained increase in protein level
we tested the protein expression of CaM in MCF-7 and ZR-
75-1 cells treated with rifampicin, anandamide or solvent
control for 24 hrs and 18 hrs respectively. These timings
correspond with when we noted up-regulation of iNOS
mRNA in these cell lines. As shown in Figure 4C, CaM
protein was up-regulated in comparison to the solvent
control, DMSO by both SXR activators in both MCF-7 and
ZR-75-1 cells. This is in accord with the notion that
increased iNOS activity requires increased CaM to stabi-
lize the newly synthesized iNOS [58]. In MCF-7 cells CaM
mRNA is down by 24 hrs but CaM protein was still up till
24 hrs by both SXR activator compounds, rifampicin and
anandamide suggesting long half-life of the protein.
Two approaches were employed to confirm that the ele-
vated levels of iNOS correspond with increased NOS
activity. First, we tested NOS activity in homogenates
made from MCF-7 cells treated with 10 μM rifampicin orBMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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SXR activation increases expression of inducible nitric oxide synthase and raises NOS activity Figure 4
SXR activation increases expression of inducible nitric oxide synthase and raises NOS activity. A) MCF-7 and B) 
ZR-75-1 cells were grown in the presence of 10 μM concentration of SXR activators compounds rifampicin, anandamide or 
clotrimazole for 24, 48 and 72 hours and for 18 and 24 hours respectively. After the indicated time of treatment, total RNA 
was isolated, reverse transcribed and analyzed by QRT-PCR using primers for the human iNOS gene. Data are shown as aver-
age fold induction relative to solvent control in triplicates ± S.E.M. Results were replicated in at least three independent exper-
iments.*represents P ≤ .05 and ** represents P ≤ .01 compared to control (by student's t test) C) SXR activation increase the 
levels of calmodulin protein in MCF-7 and ZR-75-1 cells. Equal amount of total cell lysates made from MCF-7 and ZR-75-1 cells 
treated with SXR activator compounds or solvent control for 24 and 18 hrs respectively were subjected to Western blot anal-
ysis using CaM antibody (C7055, sigma-aldrich) as described in materials and methods section. Equal loading was confirmed by 
probing with anti-GAPDH antibody. D) SXR activation increases iNOS activity. MCF-7 cells were activated by rifampicin or 
solvent control for 48 hours. Cytokine cocktail (IL1β (20 ng/ml), TNFα (15 ng/ml) and LPS(1 mg/ml) was used as a positive 
control. Nitric oxide synthase activity was determined intotal cells homogenates in the presence or absence of NOS inhibitors; 
L-NMMA and 1400 W (10 μM) as described in Materials and Methods. The data are depicted as counts per minute (CPM) per 
mg protein. The results have been replicated in independent runs. # represents P ≤ .001 in comparison to RIF (by student's t 
test) E) SXR activation leads to Nitric Oxide (NO) accumulation. MCF-7 cells were treated with SXR agonists (10 μM) or sol-
vent control for 48 hours. The concentration of nitrate plus nitrite (stable metabolites of nitric oxide) in the culture superna-
tant of SXR agonists treated or control-treated MCF-7 cells was measured using the Griess method [36]. Data are depicted as 
average fold induction relative to solvent control in triplicates ± S.E.M. The results were replicated in at least three independ-
ent experiments. *represents P ≤ .05 compared to control (by one-way ANOVA analysis). F) L-NMMA and 1400 W, the nitric 
oxide synthase inhibitors block the increase in expression of p53 caused by rifampicin. MCF-7 cells were pre-treated with or 
without L-NMMA (500 μM) or 1400 W (10 μM) for 1 hr and then stimulated by rifampicin for 72 hours. Total RNA was iso-
lated from the cells after completion of treatment and analyzed for p53 expression using QRT-PCR. The data are shown as 
average fold induction relative to solvent control in triplicates ± S.E.M. rifampicin, RIF; tamoxifen, TAM; anandamide, ANA; 
clotrimazole, CLO; camptothecin, CAMP. # represents P ≤ .001 and ** represents P ≤ .01 in comparison to RIF (by student's t 
test). rifampicin, RIF; anandamide, ANA; clotrimazole, CLO.
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solvent control for 24 and 48 hours by measuring in-vitro
biochemical conversion of 14C L-arginine into 14C L-cit-
rulline as a direct measure for iNOS activity [59]. Second,
we determined the NO concentration in cell free superna-
tant from SXR activator treated MCF-7 cells by measuring
the total nitrate plus nitrite (the stable metabolites of NO)
present in the media as an indirect measure of iNOS activ-
ity by the Greiss method [36]. Treatment of MCF-7 cells
with rifampicin elicited a significant increase in NOS
activity (Figure 4D). Treatment with a cytokine cocktail
was used as a positive control for iNOS induction [60].
The increased NOS activity by either rifampicin or by
cytokine cocktail treatment could be completely blocked
by either a non-specific NOS inhibitor, L-N(G)-mono-
methylarginine (L-NMMA) [61] or the iNOS specific
inhibitor 1400 W [62] (Figure 4D). Together, these results
confirm that the increase in NOS activity in MCF7 cells
resulting from treatment with SXR activators is primarily
due to increased iNOS levels and activity.
Consistent with increased iNOS expression and NOS
activity, the total nitric oxide level in the culture medium
of MCF-7 cells treated with 10 μM rifampicin, anandam-
ide, or clotrimazole for 48 hours were also increased (Fig-
ure 4E), confirming that iNOS-dependent increased
production of NO could be one important mechanism
through which SXR activators promote apoptosis in these
cells. As expected based on the NOS activity, NO produc-
tion was also blocked in SXR activated cells using the
inhibitors 1400 W or L-NMMA (see Additional file 1: sup-
plementary Figure 3C).
To assess whether SXR activation also affected the expres-
sion of eNOS (endothelial NOS), MCF-7 and ZR-75-1
cells were treated with 10 μM rifampicin for 24 and 18 hrs
respectively. Treatment with SXR activators selectively
increased the expression level of iNOS but not of eNOS in
both breast cancer cell lines (see Additional file 1: supple-
mentary Figure 3D). These results further support that
observed increase in NOS activity and NO by SXR activa-
tors is primarily due to increased levels of iNOS.
Since increased NO levels have been reported to lead to
p53 stabilization and activation, we next studied the
requirement for NO in the up-regulation of p53 and sub-
sequent cell cycle arrest and apoptosis that we observed in
breast cancer cells. We treated MCF-7 cells with rifampicin
in the presence or absence of L-NMMA or 1400 W, fol-
lowed by QRT-PCR to measure the expression level of
p53. Pre-treatment of MCF-7 cells with L-NMMA or 1400
W completely blocked the up-regulation of p53 observed
following rifampicin treatment (Figure 4F). Therefore, we
infer that increased cellular NO levels are required for up-
regulation of p53 and its target genes in response to SXR
activation.
Treatment with 1400 W itself activated p53 expression in
breast cancer cells (Figure 4F). Since many known drugs
activate SXR, we tested the ability of L-NMMA and 1400
W to activate SXR by measuring levels of the SXR target
gene CYP3A4. Treatment with 1400 W, but not L-NMMA,
increased CYP3A4 levels. We concluded that 1400 W acti-
vates SXR, which might explain its ability to up-regulate
p53 (see Additional file 1: supplementary Figure 3E).
Even though 1400 W can activate p53 on its own it was
still able to inhibit rifampicin induced p53 up-regulation
(Figure 4F). One possible explanation is that rifampicin is
a higher affinity ligand for SXR than is 1400 W. Thus, in
the absence of rifampicin, 1400 W can bind to and acti-
vate SXR. However, in the presence of rifampicin, the
1400 W is competed out and functions only as an iNOS
inhibitor. Although this hypothesis needs further explora-
tion, but since both of the NOS inhibitors (L-NMMA and
1400 W) were able to inhibit p53 up-regulation by SXR
activators, we infer that that the SXR activator-induced
increase in p53 expression is mediated through iNOS and
the up-regulation of p53 by 1400 W does not affect our
conclusion.
Activity of SXR is sufficient to inhibit the growth of MCF-7 
cells
Although SXR activators were able to inhibit breast cancer
cell proliferation, the compounds tested can potentially
act through other pathways to stop cancer cell growth. To
establish whether SXR activation, per se, was responsible
for the observed effects on cell proliferation, we employed
a constitutively active form of SXR [63]. This construct,
VP16-SXR, contains the strong transcriptional activation
domain from the herpes simplex virus protein VP16 fused
to the amino terminus of full length SXR-1. VP16-SXR is
transcriptionally active in the absence of added ligands
[63]. Plasmids expressing VP16-SXR and pDSRed (which
expresses a red fluorescent protein) were transiently trans-
fected into MCF-7 cells. Red fluorescing cells (which are
assumed to contain both VP16-SXR and pDSRed) were
separated from non-fluorescing cells using fluorescence-
activated cell sorting. The sorted red fluorescent cells were
cultured for an additional four days, then harvested for
cell proliferation assays. Proliferation of VP16-SXR-trans-
fected cells was strongly inhibited compared with cells
transfected with empty plasmid, or with VP16 alone (Fig-
ure 5A). Therefore, we infer that SXR activation itself
decreased the proliferation of breast cancer cells, support-
ing our model that the test compounds also exerted their
effects on proliferation through SXR.
We further confirmed our model by testing the gene
expression level of iNOS and p53 and p53 dependent tar-
get genes in VP16 or VP16-SXR transfected MCF-7 cells.
The expression of iNOS and p53 and p53 dependent
genes was strongly induced in VP16-SXR transfected cellsBMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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Activated SXR is necessary and sufficient to inhibit the growth of breast cancer cells Figure 5
Activated SXR is necessary and sufficient to inhibit the growth of breast cancer cells. A) Constitutively active SXR 
is sufficient to decrease the growth of MCF-7 cells. MCF-7 cells were transfected with VP16 or VP16-SXR in the presence of 
pDSRed, and red fluorescent cells were sorted, plated and grown for an additional 4 days. Cell proliferation was measured by 
fluorescence assay as above and the experiment was repeated at least twice. ** represents P ≤ 0.01 in comparison to VP-16 (by 
Student's t test). B) SXR expression is reduced by siRNA directed against SXR. MCF-7 cells were transfected with siRNA 
against SXR (siRNA) or scrambled siRNA (SCR) (100 nM each) for 72 hrs was tested for SXR protein expression using anti-
412 SXR antibody. The chemiluminescent bands were analyzed by spot densitometry analysis using FluorChem AlphaEase FC 
software (Alpha Innotech) C) Ligand induced up-regulation of iNOS is directly regulated by SXR. SXR-siRNA but not SCR 
transfection blocked the ability of SXR ligands (RIF and ANA) to induce up-regulation of CYP3A4 and iNOS. Un-transfected 
MCF-7 cells, or cells transfected with siRNA or SCR sequence (36 nM each) were treated with 10 μM RIF or ANA for 48 hr. 
Target gene expression was tested by QRT-PCR. The data are shown as average fold induction relative to solvent control in 
triplicates ± S.E.M. * represents P ≤ .05 in comparison to SCR (by student's t test). D) SXR activation induced apoptosis is 
blocked by SXR siRNA. Apoptosis was measured in equal number of MCF-7 cells induced with SXR activator rifampicin or sol-
vent control DMSO for 72 hours after knocking down SXR expression using SXR specific siRNA. The cells transfected with a 
non-specific scrambled siRNA or un-transfected cells were used as a control. The experiment was repeated twice in triplicates. 
The absorbance at 405 nM represents apoptotic cells and data are shown as mean absorbance in triplicates ± S.E.M. * repre-
sents P ≤ .05 in comparison to DMSO solvent control.
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in comparison to VP16 alone transfected cells (see Addi-
tional file 1: supplementary Figure 4A). This further sup-
ports our model that the SXR activator-dependent effects
on proliferation of breast cancer cells are mediated specif-
ically through SXR-induced increase in iNOS and p53 and
p53 dependent genes and not because of other properties
of the compounds.
SXR knockdown by siRNA inhibits the increased expression 
of iNOS
As a final confirmation of the requirement for SXR in the
regulation of iNOS expression and iNOS-mediated up-
regulation of p53 and its target genes in breast cancer cells,
we investigated the effects of SXR loss-of-function on the
induction of gene expression by SXR ligands. MCF-7 cells
were transfected with scrambled or SXR specific siRNA
[27,37]. Consistent with previously published reports
treatment with a specific siRNA duplex against SXR, but
not with a control scrambled siRNA, reduced the SXR
mRNA level by more than 80% (see Additional file 1: sup-
plementary Figure 4B), and protein levels by more than
50% in MCF-7 cells (Figure 5B). Rifampicin and ananda-
mide induced up-regulation of both CYP3A4 and iNOS
mRNA expression was also significantly inhibited by the
SXR siRNA in these cells (Figure 5C). Similarly the SXR
activator induced expression of p53 and p21 was also sig-
nificantly inhibited by siRNA (see Additional file 1: sup-
plementary Figure 4C).
As a final confirmation of the functional impact of SXR
knockdown, we measured apoptosis in SXR siRNA treated
cells. MCF-7 cells were transfected with scrambled or SXR
specific siRNA. 36 hours after transfection, the cells were
treated with rifampicin or solvent control. 72 hr post-
treatment apoptosis was measured in equal number of
cells using cell death detection ELISA. As shown in Figure
5D the un-transfected and SCR transfected cells showed a
significant increase in apoptosis after rifampicin treat-
ment compared with controls. In contrast, there was no
induction of apoptosis by rifampicin in MCF-7 cells trans-
fected with SXR-siRNA (Figure 5D). These results confirm
the requirement for SXR function to mediate the iNOS
and p53-dependent downstream pathways resulting in
apoptosis and cell cycle arrest described above.
Knockdown of p53 inhibits up-regulation of p21 and BAX
To further confirm that activation of SXR and its subse-
quent anti-proliferative effects in breast cancer cells are
mediated through a p53 dependent mechanism, we
knocked down p53 using siRNA. Transient transfection of
MCF-7 cells with p53 specific siRNA (siRNA) but not with
a scrambled siRNA (SCR) reduced p53 mRNA level by
more than 90% (Figure 6A) and camptothecin stabilized
p53 protein level by more than 70% (Figure 6B). As pre-
dicted, induction of p21 and BAX mRNA by rifampicin is
significantly blocked in p53 siRNA transfected, but not in
SCR siRNA transfected cells (Figure 6C). These results con-
firm the requirement of p53 for the SXR-mediated growth
inhibitory and apoptotic effects on breast cancer cells.
Discussion
The orphan nuclear receptor SXR is known to regulate the
expression of target genes involved in all three phases of
steroid and xenobiotic metabolism in the liver and gut.
However, SXR is also expressed in bone, kidney, lung,
endometrium and breast tissue [22,24-26,39]. Most of
these tissues do not contribute significantly to xenobiotic
metabolism; hence, SXR may be performing other func-
tions. Here we have defined a new mechanism by which
SXR transcriptional activation affects the growth of breast
cancer cells. Activation of SXR in ER+p53wt breast cancer
cells inhibits their proliferation through a cascade of
events beginning withinduction of iNOS and production
of NO that ultimately leads to cell cycle arrest and apop-
tosis.
Our experiments demonstrated increased steady state lev-
els of iNOS mRNA in both MCF-7 and ZR75-1 cells, as
well as increased iNOS activity accompanied by accumu-
lation of NO in MCF-7 cells treated with SXR activators.
We also observed increase in CaM mRNA and protein lev-
els following SXR activation in both MCF-7 and ZR-75-1
cells. Consistent with this observation, increased CaM is
expected to accompany induced iNOS expression since
CaM binds to, and is required for activity of newly synthe-
sized iNOS [57]. Increases in NO (48 hour post-treat-
ment) levels were followed by increased expression of
p53, and p53 target genes such as p21, BAX and PUMA
(72 hour post-treatment), which finally led to apoptosis
and G1 arrest (Figure 7) in MCF-7 cells. Other reports
demonstrated increased stability and accumulation of
p53 by NO [56] and a strong association of p53 expres-
sion with iNOS expression [55]. Previous work has also
established that accumulated p53 leads to up-regulation
of cell cycle regulatory proteins, and pro-apoptotic pro-
teins such as p21 and BAX [50,51] and induction of these
genes leads to G0/G1 arrest [50] and apoptosis
[46,47,50]. Therefore, the mechanism we have identified
links SXR activation with a well-characterized pathway
capable of mediating cell proliferation and apoptosis.
Loss-of-function and gain-of-function studies shown
above demonstrated that SXR activation is necessary and
sufficient for this pathway. Therefore, we infer that the
regulation of cell proliferation and apoptosis in response
to xenobiotic ligands in breast cancer cells is a novel cellu-
lar function for SXR that requires further exploration.
It was previously established that RNS/NO cause p53 sta-
bilization and that the stabilized p53 is transcriptionally
active [51]. NO-induced p53 stabilization is hypothesizedBMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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SXR induced apoptosis is p53 dependent Figure 6
SXR induced apoptosis is p53 dependent. A) MCF-7 cells were transiently transfected with siRNA specific against p53 
(siRNA) or scrambled siRNA (SCR) (50 nM each). The knockdown efficiency was measured by measuring mRNA (A) or pro-
tein levels of p53 (B) after 48 and 72 hours of transfection respectively. The protein bands were analyzed by FluorChem 
AlphaEase FC software (Alpha Innotech).# represents P ≤ .001 in comparison to SCR (by student's t test) C) SXR induced up-
regulation of cell cycle regulatory and apoptotic gene is dependent on p53. MCF-7 cells un-transfected (UT) or transfected 
with SCR or p53 specific siRNA (siRNA) were induced with SXR activator, rifampicin or DMSO control for 72 hours. The 
mRNA expression level of p21 and BAX was measured by QRT-PCR. The data are shown as average fold induction relative to 
DMSO control in triplicates ± S.E.M. * represents P ≤ .05 and ** represents P ≤ .01 in comparison to SCR (by student's t test).
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to result from phosphorylation at serine-15 of p53 [49].
This phosphorylated form of p53 has been associated
with attenuated p53 nuclear export [64]. In turn, nuclear
levels of activated p53 are subject to negative regulation
by Mdm2, which functionally inactivates p53, facilitates
p53 ubiquitination, nuclear export, and proteasomal deg-
radation. Whether or not phosphorylation at serine 15
disrupts the p53/Mdm2 interaction is currently controver-
sial [65]. However, it is clear that blocking p53 nuclear
export stabilizes active p53 [66] and that NO exposure
leads to nuclear p53 accumulation [56]. Moreover, expres-
sion of the iNOS gene has been shown to have a strong
association with p53 expression at both mRNA and pro-
tein levels [55]. Increased BAX, PUMA and p53 mRNA lev-
els were not observed by all three SXR activators until 72
hours in MCF-7 cells, whereas iNOS was up-regulated as
early as 24 hrs after treatment with SXR activators in our
experiments (Figure 3A and Figure 4A). This timing sup-
ports our model that the primary effect of SXR activation
in these breast cancer cells is to increase steady-state levels
of iNOS mRNA which then leads to increased production
of NO. Increased NO levels up-regulate expression of p53.
The elevated levels of p53 further up-regulate expression
of p21 and that of the pro-apoptotic p53 target genes BAX
and PUMA in breast cancer cells (Figure 7). Inhibition of
NOS blocked the induction of p53 and knock down of
p53 inhibited the induction of p21 and BAX in response
to SXR activators. Both of these results further confirmed
our model that p53 is acting down-stream of NOS and is
required for up-regulating the expression of cell cycle reg-
ulatory and pro-apoptotic genes such as p21, BAX and
PUMA in breast cancer cells in response to SXR activation.
Interestingly, expression of the cell cycle regulatory gene
p21(Waf1/Cip1) can also be induced by NO [50,67].
Moreover, nitric oxide can have cytostatic effects on cells
by directly influencing the cyclin D1 expression, inde-
pendent of p53 [54]. In our experiments MCF-7 accumu-
lated in G1/S phase of cell cycle starting as early as 24
hours post-treatment. In contrast, p53 and its target genes
did not started going up until 48 hours, indicating p53
independent cytostatic effects of nitric oxide at earlier
time points.
Model depicting cell cycle arrest and apoptosis in breast cancer cells associated with SXR activation Figure 7
Model depicting cell cycle arrest and apoptosis in breast cancer cells associated with SXR activation. SXR activa-
tion by xenobiotic ligands causes coordinated up-regulation of iNOS and its protein activator calmodulin (CaM); CaM binding 
to iNOS promotes the oxidative burst and bacterial killing or apoptosis and necrosis. Following activation of iNOS the 
increased NO levels cause stabilization of p53 protein and subsequent up-regulation of p53 mRNA [49,55]. p53 up-regulates 
cell-cycle regulatory (p21) and apoptotic genes (BAX and PUMA). The increase in p21 causes G1 arrest in cells. Ultimately, the 
unchecked increase in the levels of the pro-apoptotic genes BAX and PUMA commits the cell to undergo apoptosis. Closed 
arrows indicate genes induced or up-regulated. The open arrow indicates that CaM stabilizes iNOS, facilitating its enzymatic 
activity.BMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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Experiments in p53 null mice as well as in p53 wt versus
p53mut lymphoblastoid cells have demonstrated that NO
induces apoptosis, and that this effect is dependent upon
the presence of wild type p53 [68]. We detected elevated
NO and apoptosis in MCF-7 cells treated with SXR activa-
tors, and increases in iNOS mRNA as well as mRNAs
encoding p53 and p53-target genes in MCF-7 and ZR75-1
cell lines. Both of these cell lines are p53 wild type; there-
fore, our results are consistent with the earlier findings. As
expected, we did not observe the induction of p53 target
genes by SXR activators in cells transfected with p53 siRNA
which again emphasize the role of p53 in our model.
Previously published reports have suggested that there is
an inverse relationship between ER and SXR levels in
breast and endometrial tissues [22,25]. Both of the cell
lines tested in this study are ER positive. However, in our
preliminary experiments with ER+ and ER- breast cancer
cell lines and consistent with previously published reports
with breast cancer cell lines [25], we did not observe an
inverse relationship between ER and SXR protein levels
(data not shown). It is possible that this may be because
insufficient samples have been examined and this point
requires further exploration with bigger sample size. It
would also be of interest to see if the anti-proliferative
effects of SXR are limited to ER+ breast cancer cells.
Interestingly, in this study we also found that although
MCF-7 and ZR-75-1 cells express almost equal amount of
SXR protein (Figure 1), the MCF-7 cells were considerably
more sensitive in anti-proliferative response to SXR activa-
tors in comparison to ZR-75-1 cells (Figure 2A). There can
be many reasons for differences in the sensitivity of these
cells towards SXR activators. One plausible and likely
explanation is that ZR-75-1 cells express much lower levels
of p53 in comparison to MCF-7 cells http://www.mdander
son.org/departments/cancerbiology/dIndex.cfm?pn
=31062032-B0EB-11D4-80FB00508B603A14. The topoi-
somerase I inhibitor, camptothecin can only induce a ~3
fold increase in p53 protein levels in ZR75-1 cells com-
pared with ~18 fold increase in MCF-7 cells (please com-
pare figure 3C and Figure 3D). This is consistent with the
possibility that differences in the sensitivity of these cells to
SXR activators is more closely related to the inducibility of
p53, than to the levels of SXR.
A very recent study has shown that SXR activators increased
the expression of organic anion transporter, enhancing
estrogenic effects in breast cancer [69]. The differences in
the pro-proliferative vs. pro-apoptotic effects of SXR in this
study vs. our study can have several possible causes. There
was a different experimental design in that the other study
grew the breast cancer cells in estrogenic conditions vs. our
experiments in which the cells were grown in estrogen
depleted conditions (stripped medium, phenol red free) or
the choice of breast cancer cell lines (MCF-7 and ZR-75-1
vs. T47-D). In addition, MCF-7 cells express much lower
level of OATP1a2 than T47-D and T47-D are p53mut.
Recent studies have reported anti-apoptotic effects of SXR
in liver and colon cancer cells [29,34] and proliferative
effects in ovarian cancer cells in-vitro [70], whereas SXR
activation, in-vivo, has been suggested to have pro-apop-
totic effects in colon tissues [33]. Here we have shown that
activation of SXR is pro-apoptotic in breast cancer cells.
The ability of SXR to be pro-apoptotic in one tissue and
anti-apoptotic in others may result from cell-type specific
effects of SXR, or of SXR-induced NO. We previously,
showed that SXR can regulate gene expression in a tissue
specific manner based on the levels of co-repressor NCoR
expressed in these tissues [71]. Therefore, we propose that
SXR activation might activate a different panel of gene in
liver or colon tissue in comparison to breast tissue which
may explain its different role between tissues. Moreover,
the association between RNS/NO and apoptosis is also
very complex. RNS/NO can provoke apoptosis or alterna-
tively antagonize cell death pathways, depending on the
cell type, NO concentration, redox state of the cell, pro-
versus anti-apoptotic balance of an individual cell, and
the subcellular localization of NO synthesis (reviewed in
[53]). Therefore, the threshold levels for RNS to trigger
apoptosis will likely differ from one cell to another. Inter-
estingly, in accordance with our results different groups
have reported induction of NO by many different SXR
activators such as rifampicin, tamoxifen and anandamide
in different cell types [72-74]. These studies from different
groups suggest that SXR might commonly activate NO in
different cells but depending on the cellular milieu, SXR
generated NO can be pro-apoptotic or anti-apoptotic.
Taken together, these studies suggest that SXR may have
cell type specific effects on proliferation/apoptosis path-
ways, particularly in cancer cells.
These results also raise an intriguing question – is SXR
expression pro- or anti-proliferative in breast cancers, in
vivo? Understanding whether SXR is pro- or anti-prolifer-
ative in breast cancers is very important for optimizing
breast cancer therapies because many commonly used
chemotherapeutic agents (tamoxifen, taxol, cyclophos-
phamide, cisplatin) are SXR activators. The novel link we
have established between SXR and breast cancer requires
further investigation using appropriate in vivo systems. If,
as we have shown, SXR activation is anti-proliferative,
then therapies or preventive measures that target SXR
without inducing their own metabolism will provide an
important adjunct to current therapies. If SXR expression
promotes, rather than inhibits the growth of cancer cells,
then treatment with drugs that activate SXR will ultimately
be counterproductive to tumor treatment. In this event,
treatment of patients with standard therapies togetherBMC Cancer 2009, 9:3 http://www.biomedcentral.com/1471-2407/9/3
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with SXR antagonists [28,75], or with SXR-transparent
chemotherapeutic agents could prove beneficial both in
blocking tumor growth and in improving the therapeutic
efficacy of existing agents.
Conclusion
Taken together, the data presented above show that activa-
tion of SXR induces apoptosis in p53wt breast cancer cells
that is mechanistically dependent upon induction of iNOS
and NO-induced accumulation of p53 in cells. Our results
have established a novel link between SXR and p53 induc-
tion and apoptosis in breast cancer cells. There have been
scattered reports on xenobiotic metabolism and breast can-
cer. However, it was not clear what pathways or genetic fac-
tors are involved. Our results represent the first identification
of an association between a well established xenobiotic
receptor, SXR and apoptosis of breast cancer cells. Further in
depth studies providing mechanistic insights into the role of
SXR in proliferation and apoptosis of mammary epithelial
cells in-vivo will have significant impact on breast cancer.
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